Results 121 to 130 of about 43,226 (268)

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

open access: yesBritish Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral   +3 more
wiley   +1 more source

KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4

open access: yesCancer Science, EarlyView.
KYNU is upregulated in gastric cancer cells and activates the PI3K/Akt pathway, leading to PF4 secretion. PF4 drives nonclassical macrophage polarization with high expression of S100A8 and MMP7, which promotes tumor proliferation, migration, and invasion while suppressing phagocytosis, thereby accelerating gastric cancer progression.
Xilun Cui   +4 more
wiley   +1 more source

Changes in gastrointestinal motility and gut hormone secretion after Roux‐en‐Y gastric bypass and sleeve gastrectomy for individuals with severe obesity

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink   +4 more
wiley   +1 more source

iPSC‐Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice

open access: yesCell Proliferation, EarlyView.
Infusion of CXCR4‐expressing iNK progenitor (iNKP) cells derived from iPSCs can continuously generate iNK cells in an unconditioned and autologous PBMC humanised hIL15 mouse model. iNKP cell therapy has the potential to treat patients without the requirement for prior lymphodepletion. ABSTRACT NK cells exhibit inherently short persistence in vivo. Allo‐
Min Zhang   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy